Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 43, Issue 1, 2005, Pages 37-42

  Setoyama, Tsutomu ^a   Laurent, A ^b   Humphries, T ^c   Hasegawa, J ^d  

^a EISAI RESEARCH INSTITUTE   (United States)

^b Pharmaceutical Product Development   (United States)

^c Ferring Pharmaceuticals Inc   (United States)

^d EISAI CO LTD   (Japan)

Author keywords

Absolute bioavailability; Pharmacokinetics; Proton pump inhibitor; Rabeprazole

Indexed keywords

RABEPRAZOLE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SINGLE DRUG DOSE; VISUAL DISORDER;

EID: 12344278016     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP43037     Document Type: Article

References (21)

1. Andersson T, Cederberg C, Regårdh CG, Skånberg I 1990a Pharmacokinetics of various single intravenous and oral doses of omeprazole. Ent J Clin Pharmacol 39: 195-197
2. Andersson T, Andrén K, Cederberg C, Heggelund A, Lundborg P, Röhss K 1990b Bioavailability of omeprazole as enteric-coated (EC granules in conjunction with food on the first and seventh days of treatment. Drug Invest 2: 184-188
3. Andersson T, Cederberg C, Heggelund A, Lundborg P 1991 The pharmacokinetics of single and repeated once-daily doses of 10, 20 and 40 mg omeprazole as enteric-coated granules. Drug Invest 3: 45-52
4. Beierle I, Meibohm B, Derendorf H 1999 Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 37: 529-547
5. Besancon M, Simon A, Sachs G, Shin JM 1997 Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 272: 22438-22446
6. Fujisaki H, Shibata H, Oketani K, Murakami M, Fujimoto M, Wakabayashi T, Yamatsu I, Yamaguchi M, Sakai H, Takeguchi N 1991 Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione. Biochem Pharmacol 42: 321-328
7. Gerloff J, Mignot A, Barth H, Heintze K 1996 Pharmacokinetics and absolute bioavailability of lansoprazole. Eur J Clin Pharmacol 50: 293-297
8. Hoyumpa AM, Trevino-Alanis H, Grimes I, Humphries TJ 1999 Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis. Clin Ther 21: 691-701
9. Keane WF, Swan SK, Grimes I, Humphries TJ 1999 Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure. J Clin Pharmacol 39: 927-933
10. Laurent AL, Merritt GJ, Setoyama T, Humphries TJ 1999 Rabeprazole: pharmacokinetics and safety in the elderly. Clin Geriatr 7: 27-33
11. Lew EA, Barbuti RC, Kovacs TO, Stynic B, Humphries TJ, Walsh JH 1998 An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810). Aliment Pharmacol Ther 12: 667-672
12. Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L 1983 Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin-stimulated acid secretion in man. Gut 24: 270-276
13. +-ATPase is correlated with the rate of acid activation of the inhibitor. Biochem Pharmacol 39: 661-667
14. + ATPase inhibitor (E3810) and its four metabolites in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl 660: 211-220
15. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL 2003 Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 17: 1507-1514
16. Pue MA, Laroche J, Meineke I, de May C 1993 Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. Eur J Clin Pharmacol 44: 575-578
17. Regårdh CG, Andersson T, Lagerström PO, Lundborg P, Skånberg I 1990 The pharmacokinetics of omeprazole in humans - a study of single intravenous and oral doses. Ther Drug Monit 12: 163-172
18. Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L 2002 Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther 16: 445-454
19. Williams MP, Sercombe J, Hamilton MI, Puonder RE 1998 A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 12: 1079-1089
20. Yasuda S, Ohnishi A, Ogawa T, Tomono Y, Hasegawa J, Nakai H, Shimamura Y, Morishita N 1994 Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther 32: 466-473
21. Yasuda S, Higashi S, Murakami M, Tomono Y, Kawaguchi M 1999 Antiacids have no influence on the pharmacokinetics of rabeprazole, a new proton pump inhibitor, in healthy volunteers. Int J Clin Pharmacol Ther 37: 249-253